Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: A systematic review and meta-analysis

Irbaz Bin Riaz, Umar Zahid, Muhammad Umar Kamal, Muhammad Husnain, Ali McBride, Anh Hua, Auon Abbas Hamadani, Laeth George, Ali Zeeshan, Qurat Ul Ain Riaz Sipra, Ammad Raina, Bushra Rahman, Soham Puvvada, Faiz Anwer

Research output: Research - peer-reviewReview article

Abstract

Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 chimeric antigen receptor-T therapy for B-cell hematologic malignancies. A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate of 61% (118/195) with complete response of 42% (81/195) and partial response of 19% (37/195). Major adverse events were cytokine release syndrome 33%, neurotoxicity 33% and B-cell aplasia 54%. Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia, especially in acute lymphoblastic leukemia (ALL) patients.

LanguageEnglish (US)
Pages979-993
Number of pages15
JournalImmunotherapy
Volume9
Issue number12
DOIs
StatePublished - Sep 1 2017

Fingerprint

Meta-Analysis
B-Lymphocytes
T-Lymphocytes
Neoplasms
Hematologic Neoplasms
Neurotoxicity Syndromes
Antigen Receptors
T-Cell Antigen Receptor
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Leukemia
Clinical Trials
Cytokines
Safety
Therapeutics

Keywords

  • chimeric antigen T cells
  • hematological malignancy
  • leukemia
  • lymphoma
  • refractory
  • relapse

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies : A systematic review and meta-analysis. / Riaz, Irbaz Bin; Zahid, Umar; Kamal, Muhammad Umar; Husnain, Muhammad; McBride, Ali; Hua, Anh; Hamadani, Auon Abbas; George, Laeth; Zeeshan, Ali; Sipra, Qurat Ul Ain Riaz; Raina, Ammad; Rahman, Bushra; Puvvada, Soham; Anwer, Faiz.

In: Immunotherapy, Vol. 9, No. 12, 01.09.2017, p. 979-993.

Research output: Research - peer-reviewReview article

Riaz, IB, Zahid, U, Kamal, MU, Husnain, M, McBride, A, Hua, A, Hamadani, AA, George, L, Zeeshan, A, Sipra, QUAR, Raina, A, Rahman, B, Puvvada, S & Anwer, F 2017, 'Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: A systematic review and meta-analysis' Immunotherapy, vol 9, no. 12, pp. 979-993. DOI: 10.2217/imt-2017-0062
Riaz IB, Zahid U, Kamal MU, Husnain M, McBride A, Hua A et al. Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: A systematic review and meta-analysis. Immunotherapy. 2017 Sep 1;9(12):979-993. Available from, DOI: 10.2217/imt-2017-0062
Riaz, Irbaz Bin ; Zahid, Umar ; Kamal, Muhammad Umar ; Husnain, Muhammad ; McBride, Ali ; Hua, Anh ; Hamadani, Auon Abbas ; George, Laeth ; Zeeshan, Ali ; Sipra, Qurat Ul Ain Riaz ; Raina, Ammad ; Rahman, Bushra ; Puvvada, Soham ; Anwer, Faiz. / Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies : A systematic review and meta-analysis. In: Immunotherapy. 2017 ; Vol. 9, No. 12. pp. 979-993
@article{42cf41f601cf4fc68e2ed1ca6d71cca8,
title = "Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: A systematic review and meta-analysis",
abstract = "Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 chimeric antigen receptor-T therapy for B-cell hematologic malignancies. A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate of 61% (118/195) with complete response of 42% (81/195) and partial response of 19% (37/195). Major adverse events were cytokine release syndrome 33%, neurotoxicity 33% and B-cell aplasia 54%. Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia, especially in acute lymphoblastic leukemia (ALL) patients.",
keywords = "chimeric antigen T cells, hematological malignancy, leukemia, lymphoma, refractory, relapse",
author = "Riaz, {Irbaz Bin} and Umar Zahid and Kamal, {Muhammad Umar} and Muhammad Husnain and Ali McBride and Anh Hua and Hamadani, {Auon Abbas} and Laeth George and Ali Zeeshan and Sipra, {Qurat Ul Ain Riaz} and Ammad Raina and Bushra Rahman and Soham Puvvada and Faiz Anwer",
year = "2017",
month = "9",
doi = "10.2217/imt-2017-0062",
volume = "9",
pages = "979--993",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies

T2 - Immunotherapy

AU - Riaz,Irbaz Bin

AU - Zahid,Umar

AU - Kamal,Muhammad Umar

AU - Husnain,Muhammad

AU - McBride,Ali

AU - Hua,Anh

AU - Hamadani,Auon Abbas

AU - George,Laeth

AU - Zeeshan,Ali

AU - Sipra,Qurat Ul Ain Riaz

AU - Raina,Ammad

AU - Rahman,Bushra

AU - Puvvada,Soham

AU - Anwer,Faiz

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 chimeric antigen receptor-T therapy for B-cell hematologic malignancies. A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate of 61% (118/195) with complete response of 42% (81/195) and partial response of 19% (37/195). Major adverse events were cytokine release syndrome 33%, neurotoxicity 33% and B-cell aplasia 54%. Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia, especially in acute lymphoblastic leukemia (ALL) patients.

AB - Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 chimeric antigen receptor-T therapy for B-cell hematologic malignancies. A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate of 61% (118/195) with complete response of 42% (81/195) and partial response of 19% (37/195). Major adverse events were cytokine release syndrome 33%, neurotoxicity 33% and B-cell aplasia 54%. Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia, especially in acute lymphoblastic leukemia (ALL) patients.

KW - chimeric antigen T cells

KW - hematological malignancy

KW - leukemia

KW - lymphoma

KW - refractory

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=85030629419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030629419&partnerID=8YFLogxK

U2 - 10.2217/imt-2017-0062

DO - 10.2217/imt-2017-0062

M3 - Review article

VL - 9

SP - 979

EP - 993

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 12

ER -